Federal regulators approved the first of a new class of cholesterol-lowering medicines, developed by Regeneron and Sanofi. The drug, called Praluent, provides a new option for high-risk heart patients.
WSJ.com: What's News US, Wall Street Journal
Fri, 07/24/2015 - 1:21pm
Federal regulators approved the first of a new class of cholesterol-lowering medicines, developed by Regeneron and Sanofi. The drug, called Praluent, provides a new option for high-risk heart patients.